在模型引导的药物研发模式和群体药代动力学研究指南(征求意见稿)发布之际，必将在中国医药研发领域掀起新的热潮，刘东阳教授将结合自身丰富的科研和工作经验和案例，给大家分享群体药代药效动力学在新药临床开发中的应用和挑战。
嘉宾介绍
刘东阳 博士，副研究员
北医三院药物临床试验机构副主任；
临床药理与定量药理研究室负责人，副研究员；
刘东阳，博士，北医三院药物临床试验机构副主任，兼任其临床药理与定量药理研究室负责人，副研究员。他在中国协和医科大学获得临床药理学博士，之后依次在美国SUNY at Buffalo药学系、美国FDA/CDER/OCP2进行PK/PD研究，并于英国曼彻斯特大学获定量药理学硕士，于2019年加入北医三院。到目前为止，他共负责或参与70余项早期临床试验，并在Clinical Infectious Disease, Clin. Pharmacokinet., Lung Cancer, Eur J Pharm Sci.等杂志发表SCI文章30多篇，主持十三五重大新药创制项目子课题、国自然基金、比尔盖茨梅琳达基金等项目。目前被聘为Journal of Pharmacokinetics and Pharmacodynamics（JPKPD）和Endocrine, Metabolic & Immune Disorders - Drug Targets（EMIDDT）杂志编委、中国药理学会定量药理委员会副主任委员、药物代谢委员会青委会常委和中国药科大学校外导师等。
主要研究方向包括：
1）代谢性、心血管和肿瘤疾病领域创新药的早期临床开发；
2）临床药理学与定量药理学研究。
近期的科研成果：
1. M Zhang, X Yao, C Cui, X Liu, H Li, D Liu#. Commentary to Simulation of Drug in the Lung can be misleading. Clin Infect Dis; 2020. SCI 8.313 (Epub online ahead) (Corresponding Author)
2. X Yao, F Ye, M Zhang, C Cui, B Huang, P Niu, X Liu, L Zhao, E Dong, C Song, S Zhan, R Lu, H Li#, W Tan#, D Liu#. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. SCI 8.313 (Epub online ahead) (First Co-corresponding Author)
3. C Cui, M Zhang, X Yao, S Tu, Z Hou, En VS Jie, H Li#, S Zhang#, D Liu#. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model. Acta Pharm Sin B 2020. SCI 7.091 (Epub online ahead) (First Co-corresponding Author)
4. X Yao, Z Hou, C Cui, M Zhang, S Tu, H Li#, D Liu#. Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population. Curr Drug Metab 2020. SCI2.659 (Epub online ahead) (First Co-corresponding Author)
5. C Cui, S Tu, VSJ En, X Li, X Yao, H Li#, D Liu#. Review on the clinical pharmacology of hydroxychloroquine sulfate for the treatment of COVID-19. Curr Drug Metab 2020. SCI2.659 (Epub online ahead) (First Co-corresponding Author)
6. L Song, Z Yu, Y Xu, X Li, X Liu, D Liu#, T Zhou#. Preliminary Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Chinese Pregnant Women. Biopharm Drug Dispos 2020. SCI2.091 (First Co-corresponding Author)
7. L Song, X Yao, Y Liu, W Zhong, J Jiang, H Liu, H Zhou, C Shi, D Liu#, P Hu#: Translational Prediction of first-in-human Pharmacokinetics and Pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using Allometric Scaling, Dedrick and PK/PD Modeling Methods. Eur J Pharm Sci 2020 :105281. SCI 3.616 (First Co-corresponding Author)
